Alcohol use disorders
Conditions
Interventions
Aripiprazole was administered orally at 3mg once a day for 8weeks.
Placebo was administered orally once a day for 8 weeks.
Sponsors
Department of Psychiatry, Chiba University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with Alcohol use diorders by DSM-IV-TR 2. Patients with 15 or over in AUDIT(the Alcohol Use Disorders Identification Test) 3. Patients with experience that failed in abstinence from alcoholic drinks befere, and who continues drinking 4.Patients with 20-64 years of age at study entry 5. Written informed consent by patients
Exclusion criteria
Exclusion criteria: 1. Comatose state 2. Influence of the central nerve inhibitor such as a barbituric acid derivative, the anesthetic 3. Current use of any other dopamine D2 agonist or antagonist 4. Current use of any other antialcoholic drug 5. Other current drug abuse or dependence 6. Use of epinephrine 7. Allergy or hypersensitivity to aripiprazole 8. Woman during pregnancy or shortly after childbirth 9. High suicidal risk 10. Uncontrollable diabetic 11. Decreased liver function (aminotransferase greater than 5 times normal) or cirrhosis more than Child C 12. Current major psychiatric disorder 13. Current dementia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of change of carbohydrate-deficient transferrin (%CDT) in the 4week and the 12 week | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Days abstinent from drinking 2. Drinks per day 3. Drinks per drinking day 4. The obsessive-compulsive drinking scale(OCDS) 5. Electroencephalography(Voluntary participation) | — |
Countries
Japan
Contacts
Public ContactTasuku Hashimoto
Chiba University Graduate School of Medicine Department of Psychiatry
Outcome results
None listed